Mar 26, 2019 - Can these big high-flying stocks keep the momentum going?
Mar 29, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Apr 02, 2019 - Advaxis' (ADXS) immunotherapy candidate, ADXS-PSA, achieves favorable overall survival in mCRPC patients in combination with Merck's Keytruda.
Apr 02, 2019 - Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting in China.
Apr 08, 2019 - Aeglea (AGLE) reports new positive data for pegzilarginase in patients with Arginase 1 Deficiency.
Apr 10, 2019 - AstraZeneca (AZN) and Merck gain an EU approval for Lynparza as a monotherapy for treating HER2-negative locally-advanced/metastatic breast cancer.
Apr 11, 2019 - Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
Apr 12, 2019 - Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
Apr 15, 2019 - FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Apr 18, 2019 - Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.